![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
March 31, 2021
The EA9171 phase II trial aims to determine if adding pembrolizumab immunotherapy to standard-of-care TKI therapy helps more patients achieve undetectable minimal residual disease and allows them to discontinue TKI therapy
March 31, 2021
March 31, 2021
February 25, 2021
COVID-19 vaccination and patients with cancer; the impact of delayed screening; a virtual Spring 2021 Group Meeting
February 25, 2021
This three-arm phase II study, led by Dr. Dan Zandberg, is evaluating pembrolizumab immunotherapy after surgery in patients with recurrent or second primary head and neck cancer with high-risk features
February 25, 2021
The randomized EAA181 phase III trial seeks to determine whether there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients
February 25, 2021
A Standing Main Member of ECOG-ACRIN since 2007
February 25, 2021
January 25, 2021
The co-chairs look ahead to the new year, and acknowledge key successes from 2020—despite its many challenges
January 25, 2021
This phase III study, led by Dr. Alicia Morgans, is exploring a new treatment option for patients with prostate cancer with high-risk features
January 25, 2021
This phase II/III study, led by Dr. Shishir Maithel, is assessing the role of neoadjuvant therapy for patients with incidental gallbladder cancer
January 25, 2021
Dr. Sparano discusses the scientific and statistical collaboration behind a new tool, RSClin™, which integrates clinical–pathological and genomic risk information to guide adjuvant chemotherapy in node-negative breast cancer